Dapagliflozin (Forxiga®). HTA ID: 22030

Assessment Status Rapid review complete
HTA ID 22030
Drug Dapagliflozin
Brand Forxiga®
Indication Indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction.
Assessment Process
Rapid review commissioned 09/05/2022
Rapid review completed 03/06/2022
Rapid review outcome A full HTA is not recommended. The NCPE recommends that dapagliflozin be considered for reimbursement*

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

The HSE has approved reimbursement. November 2023.